2 active not recruiting. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 2 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Array Biopharma: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab Phase Ib ARRY-614 + nivolumab, Phase Ib ARRY-614 + nivolumab+ipilimumab, Phase II ARRY-614 + nivolumab - Renal Cell Carcinoma, Melanoma | Phase 1 / Phase 2 | Active not recruiting | Dan Zandberg | 70 | 2020-06-11 | 2025-11-06 |
| Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer Anti-OX40 Antibody PF-04518600, Avelumab, Binimetinib - Stage III Breast Cancer, Stage IIIA Breast Cancer | Phase 2 | Active not recruiting | Laura Huppert, MD, BA | 145 | 2019-07-08 | 2026-04-17 |
Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Melanoma (1) · Squamous Cell Carcinoma of Head and Neck (1) · Triple Negative Breast Neoplasms (1)
Nivolumab (1) · avelumab (1) · binimetinib (1) · liposomal doxorubicin (1) · sacituzumab govitecan (1) · utomilumab (1)
United States (2)
Dan Zandberg, MD (1) · Laura Huppert, MD (1)